HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Diabetic peripheral neuropathy — Clinical Guidelines

Overview

Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus characterized by nerve damage, leading to symptoms such as pain, numbness, and tingling, particularly in the extremities. It significantly impacts quality of life and functional capacity 1 7.

Diagnosis

Clinical Symptoms: Presence of neuropathic pain, numbness, tingling, or weakness in extremities 1 7.

Neurological Examination: Assessment of reflexes, sensation, and muscle strength 1.

Quantitative Sensory Testing (QST): Objective measurement of sensory function 1.

Nerve Conduction Studies (NCS): To confirm peripheral nerve damage 1.

Grading: Utilize scales like the Neuropathy Impairment Score (NIS) or Michigan Neuropathy Screening Instrument (MNSI) for severity assessment 1.

Management

First-Line Treatments:

- Duloxetine: 60 mg daily for pain relief in diabetic peripheral neuropathic pain (DPNP) 16 (Evidence: Strong). - Pregabalin: Typically 300-600 mg/day, though not explicitly mentioned, often used off-label 7 (Evidence: Moderate).

Adjunctive Treatments:

- Capsaicin 8% Patch: Applied topically for pain relief 7 (Evidence: Moderate). - Gene Therapy (VM202): Plasmid DNA encoding human hepatocyte growth factor; efficacy demonstrated in phase III trials 6 (Evidence: Strong). - Vitamin D Supplementation: Consider in deficient patients, especially in elderly populations 5 9 10 (Evidence: Moderate).

Non-Pharmacological Approaches:

- Psychological Interventions: Cognitive-behavioral therapy and other psychological support to manage pain perception 8 (Evidence: Moderate). - Spinal Cord Stimulation (SCS): Effective for long-term pain management in severe cases, with success rates noted over 5 years 12 (Evidence: Moderate).

Special Populations

Elderly: Higher risk of polypharmacy and severe adverse drug events; careful medication management advised 2 4 11 (Evidence: Strong).

Comorbidities: Comorbid depression or anxiety correlates with increased healthcare utilization and costs 15 (Evidence: Strong).

Vitamin D Levels: Association with DPN severity varies by age; elderly patients more likely to show significant associations 9 10 (Evidence: Moderate).

Key Recommendations

Use Duloxetine for Pain Management in DPN: 60 mg daily for adults with DPN (Evidence: Strong) 16.

Consider Vitamin D Supplementation in Deficient Elderly Patients: To potentially mitigate neuropathic symptoms (Evidence: Moderate) 5 9 10.

Implement Careful Polypharmacy Management in Elderly Patients: To reduce risk of severe adverse drug events (Evidence: Strong) 2 4 11.

Evaluate Psychological Interventions for Pain Management: Especially beneficial for psychological aspects of chronic pain in DPN (Evidence: Moderate) 8.

Monitor and Manage Comorbid Conditions: Address depression and anxiety to improve treatment outcomes and reduce healthcare costs (Evidence: Strong) 15.

References

1 Hu J, Wang H, Hao X, Pan T, Li X, Zhou X et al.. Traditional Chinese medicine for diabetic peripheral neuropathy: a network meta-analysis. Frontiers in endocrinology 2025. link 2 Elhosseiny AA, Eldawlatly S, Ramadan E, Börsch-Supan A, Salama M. Optimizing elderly care: A data-driven AI model for predicting polypharmacy risk in the elderly using SHARE data. Neuroscience 2025. link 3 Kulenovic A, Lagumdzija-Kulenovic A. Minimizing STOPP and Beers Criteria Risks in PIM Treatments Using PM-TOM and ChatGPT: A Case Study. Studies in health technology and informatics 2025. link 4 Kim GJ, Lee JS, Jang S, Lee S, Jeon S, Lee S et al.. Polypharmacy and Elevated Risk of Severe Adverse Events in Older Adults Based on the Korea Institute of Drug Safety and Risk Management-Korea Adverse Event Reporting System Database. Journal of Korean medical science 2024. link 5 Hassan AB, Ahmed Al-Dosky AH. Association between vitamin D status and malondialdehyde in T2DM patients with painful diabetic peripheral neuropathy. Cellular and molecular biology (Noisy-le-Grand, France) 2023. link 6 Kessler JA, Shaibani A, Sang CN, Christiansen M, Kudrow D, Vinik A et al.. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clinical and translational science 2021. link 7 Abrams RMC, Pedowitz EJ, Simpson DM. A critical review of the capsaicin 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. Expert review of neurotherapeutics 2021. link 8 Racaru S, Sturt J, Celik A. The Effects of Psychological Interventions on Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Pain management nursing : official journal of the American Society of Pain Management Nurses 2021. link 9 Ou Y, Liang Z, Yang Y, Zhou YK. Association of Diabetic Peripheral Neuropathy with Vitamin D Levels Depends on Vitamin D Status. Medical science monitor : international medical journal of experimental and clinical research 2021. link 10 Niu Y, Li J, Peng R, Zhao X, Wu J, Tang Q. Low vitamin D is associated with diabetes peripheral neuropathy in older but not in young and middle-aged patients. Diabetes/metabolism research and reviews 2019. link 11 Santos-Pérez MI, Fierro I, Salgueiro-Vázquez ME, Gallardo-Lavado MDM, Sáinz-Gil M, Martín-Arias LH. A polypharmacy risk prediction model for elderly patients based on sociodemographic and clinical factors. International journal of clinical pharmacology and therapeutics 2018. link 12 van Beek M, Geurts JW, Slangen R, Schaper NC, Faber CG, Joosten EA et al.. Severity of Neuropathy Is Associated With Long-term Spinal Cord Stimulation Outcome in Painful Diabetic Peripheral Neuropathy: Five-Year Follow-up of a Prospective Two-Center Clinical Trial. Diabetes care 2018. link 13 Johnston SS, Udall M, Alvir J, McMorrow D, Fowler R, Mullins D. Characteristics, treatment, and health care expenditures of Medicare supplemental-insured patients with painful diabetic peripheral neuropathy, post-herpetic neuralgia, or fibromyalgia. Pain medicine (Malden, Mass.) 2014. link 14 Benza AT, Calvert S, McQuown CB. Prevention BINGO: reducing medication and alcohol use risks for older adults. Aging & mental health 2010. link 15 Boulanger L, Zhao Y, Foster TS, Fraser K, Bledsoe SL, Russell MW. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. Current medical research and opinion 2009. link 16 Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S et al.. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006. link 17 Shakib S. Problems of polypharmacy. Australian family physician 2002. link

Diabetic peripheral neuropathy